logo-loader
viewZelira Therapeutics Ltd

Zelda shareholders granted priority on float of CannPal Animal Therapeutics

CannPal is a pet pharmaceutical company and has lodged a prospectus with ASIC.

Zelda shareholders granted priority on float of CannPal Animal Therapeutics
CannPal is a pet pharmaceutical company

Zelda Therapeutics Ltd (ASX:ZLD) has a strategic collaborative partnership with CannPal Animal Therapeutics, which is in the process of listing on the ASX.

The companies are looking to exploit opportunities of mutual interest in both the human and animal pharmaceutical markets through the sharing of research data compiled by each of the parties.

CannPal is looking to strengthen the ties between the companies by inviting Zelda shareholders to participate as a priority applicant in the prospectus capital raising lodged with ASIC.

The prospectus is to raise $6 million.

Prospectus and offer details

Under the prospectus, 5 million shares at $0.20 have been allocated and made available to Zelda shareholders registered on the 1st September 2017 holding a minimum of 25,000 shares.

The minimum subscription in CannPal is 10,000 shares worth $2,000.

Quick facts: Zelira Therapeutics Ltd

Price: 0.036 AUD

ASX:ZLD
Market: ASX
Market Cap: $34.79 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Zelira Therapeutics releases interim data for Phase II...

Zelira Therapeutics Ltd (ASX:ZLD) managing director Dr Richard Hopkins, chairman Osagie Imasogie and clinical trial principal investigator Professor Peter Eastwood, of the University of Western Australia, update Proactive on results from the company’s Phase II clinical trial of medicinal...

on 21/2/20

2 min read